I would think that Merck would be very happy with the results. And, my personal opinion is, they "unblinded" the data before they signed the new deal with Ariad, in order to see if the drug was worth spending more money on. (The trial abstract said that unblinding was "unplanned").
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.